Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer

Abstract

Objective To investigate tumour suppressor gene TP53 mutation, clinicopathological features and prognosis in the patients with triple-negative breast cancer (TNBC). Methods The rate and distribution of TP53 mutation, clinicopathological features, and prognosis in the patients with TNBC and with surgery at our center from January 2012 to March 2019 were retrospectively analyzed. Results In total of 234 TNBC cases, 144 (61.54%) cases were with TP53 mutation type and 90 (38.46%) cases with TP53 wild type. Most mutation was located at exon 5-8 region. The cases with TP53 mutation were divided into the group of missense mutation 85(59.03%) cases and the group of non-missense mutation 59 (40.97%) cases. More cases with TP53 mutation type had higher proliferation antigen(Ki-67) expression (>30%) when compared with the cases with TP53 wild type (80.56% vs. 63.33%, P=0.004, OR=2.40). There was no significant diffe-rence in prognosis between the group of mutation type and the group of wild type in relapse-free survival (RFS) (P=0.447), overall survival (OS) (P=0.083), and distant relapse-free survival (DRFS) (P=0.131). Similarly, there was no significant difference in prognosis between TP53 missense mutation and non-missense mutation in RFS(P=0.226), OS(P=0.885), and DRFS(P=0.172). Conclusions TNBC patients with TP53 mutation exhibited higher Ki-67 expression, however, similar prognosis between TP53 mutation type and wild type.

Keywords

• |breast cancer|triple-negative breast cancer|tp53|gene mutation|prognosis